Taysha Gene Therapies, Inc.
TSHA
|
$2.265
-6.02%
-6.4%
1.8M
|
Health Technology
(0.0% 1d) (-26.8% 1m) (221.1% 1y) (-5.8% 2d) (-7.3% 3d) (-14.7% 7d) (-9.08% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 423,596,393
http://www.tayshagtx.com
Sec Filling | Patents | 38 employees
Taysha Gene Therapies, Inc. engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II on September 20, 2019 and is headquartered in Dallas, TX.
gene therapies nervous system aav capsids treatment
add to watch list Paper trade email alert is off
Press-releases
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-04-05 (Crawled : 12:00) - globenewswire.com
TSHA | $2.265 -6.02% -6.4% 1.8M
|
Health Technology
|
| O: -3.97%
H: 2.07%
C: 0.75%
nasdaq grant
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
Published: 2024-03-19 (Crawled : 20:00) - globenewswire.com
TSHA | $2.265 -6.02% -6.4% 1.8M
|
Health Technology
|
| O: 31.11%
H: 7.67%
C: 0.34%
year financial results
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
Published: 2024-03-14 (Crawled : 21:00) - globenewswire.com
TSHA | $2.265 -6.02% -6.4% 1.8M
|
Health Technology
|
| O: 1.4%
H: 10.6%
C: 5.99%
conference financial
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-03-01 (Crawled : 22:00) - globenewswire.com
TSHA | $2.265 -6.02% -6.4% 1.8M
|
Health Technology
| Email alert
Add to watchlist
nasdaq grant
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome
Published: 2024-02-29 (Crawled : 13:00) - globenewswire.com
TSHA | $2.265 -6.02% -6.4% 1.8M
|
Health Technology
|
| O: 2.65%
H: 21.03%
C: 16.61%
tsha-102 program
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs
Published: 2024-02-15 (Crawled : 21:00) - globenewswire.com
TSHA | $2.265 -6.02% -6.4% 1.8M
|
Health Technology
|
| O: 0.0%
H: 21.38%
C: 20.13%
update pipeline
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-02 (Crawled : 13:00) - globenewswire.com
TSHA | $2.265 -6.02% -6.4% 1.8M
|
Health Technology
|
| O: -1.28%
H: 1.3%
C: -1.95%
nasdaq grant
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 2, 2024
Published: 2024-02-02 (Crawled : 14:30) - biospace.com/
TSHA | $2.265 -6.02% -6.4% 1.8M
|
Health Technology
|
| O: -1.28%
H: 1.3%
C: -1.95%
nasdaq grant
Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference
Published: 2024-01-22 (Crawled : 13:00) - globenewswire.com
TSHA | $2.265 -6.02% -6.4% 1.8M
|
Health Technology
|
| O: 0.69%
H: 7.93%
C: 2.76%
tsha-102 conference association presentation
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
Published: 2024-01-10 (Crawled : 13:00) - globenewswire.com
TSHA | $2.265 -6.02% -6.4% 1.8M
|
Health Technology
|
| O: -1.04%
H: 3.68%
C: -6.32%
tsha-102 first reveal trial
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10